TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, NCE604, NCE611, and NBP. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. TiumBio Co., Ltd. is based in Seongnam-si, South Korea.
Stock data | 2024 | Change |
---|---|---|
Price | $4.64 | N/A |
Market Cap | $114.34M | N/A |
Shares Outstanding | 24.62M | N/A |
Employees | 51.00 | N/A |